Controlled-release hydromorphone and risk of infection in adults: a systematic review
Abstract Background Preliminary evidence suggests that people who inject drugs (PWID) may be at an increased risk of developing infective endocarditis (IE), hepatitis C virus (HCV) infection, and/or human immunodeficiency virus (HIV) infection from hydromorphone controlled-release formulation. The h...
Main Authors: | Andrea C. Tricco, Amanda Parker, Areej Hezam, Vera Nincic, Fatemeh Yazdi, Yonda Lai, Charmalee Harris, Zachary Bouck, Ahmed M. Bayoumi, Sharon E. Straus |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Harm Reduction Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12954-023-00788-9 |
Similar Items
-
Clinical Application of Different Doses of Hydromorphone Slow-Release Analgesia in Lumbar Fusion in Elderly Patients
by: Xianwei Jin, et al.
Published: (2024-07-01) -
Two orthorhombic polymorphs of hydromorphone
by: Jaroslaw Mazurek, et al.
Published: (2016-05-01) -
Hydromorphone Prescription for Pain in Children—What Place in Clinical Practice?
by: Frédérique Rodieux, et al.
Published: (2022-04-01) -
The Application of Hydromorphone Combined with Low-dose Promethazine in Elderly Patients with End-stage Cancer Pain
by: Yang Ying, et al.
Published: (2024-11-01) -
Erratum: Hydromorphone prescription for pain in children—What place in clinical practice?
by: Frontiers Production Office
Published: (2023-03-01)